{"nctId":"NCT00295633","briefTitle":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","startDateStruct":{"date":"2006-03"},"conditions":["Diabetes Mellitus, Type 2"],"count":565,"armGroups":[{"label":"Saxagliptin plus open-label TZD (A)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: pioglitazone","Drug: rosiglitazone","Drug: metformin"]},{"label":"Saxagliptin plus open-label TZD (B)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: pioglitazone","Drug: rosiglitazone","Drug: metformin"]},{"label":"Placebo plus open-label TZD (C)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: pioglitazone","Drug: rosiglitazone","Drug: metformin"]}],"interventions":[{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Placebo","otherNames":[]},{"name":"pioglitazone","otherNames":[]},{"name":"rosiglitazone","otherNames":[]},{"name":"metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetics currently receiving a stable dose of TZD monotherapy (pioglitazone 30mg or 45mg, or rosiglitazone 4mg or 8mg) for at least 12 weeks prior to screening.\n* Hemoglobin A1c (HbA1c) \\> = 7.0% and \\< = 10.5%\n* Body mass index \\< = 45kg/m2\n* Fasting C-peptide \\> = 1 ng/mL\n\nExclusion Criteria:\n\n* Symptomatic poorly controlled diabetes\n* Recent cardiac or cerebrovascular event\n* Serum creatinine \\> = 2.0 mg/dL","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"77 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24","description":"Mean change from baseline in A1C at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.25","spread":"0.080"},{"groupId":"OG001","value":"8.35","spread":"0.080"},{"groupId":"OG002","value":"8.19","spread":"0.080"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.59","spread":"0.098"},{"groupId":"OG001","value":"7.39","spread":"0.086"},{"groupId":"OG002","value":"7.91","spread":"0.100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"0.074"},{"groupId":"OG001","value":"-0.94","spread":"0.075"},{"groupId":"OG002","value":"-0.30","spread":"0.076"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":"Mean change from baseline in FPG at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163.0","spread":"3.54"},{"groupId":"OG001","value":"159.5","spread":"3.34"},{"groupId":"OG002","value":"162.4","spread":"3.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148.2","spread":"3.36"},{"groupId":"OG001","value":"143.0","spread":"3.20"},{"groupId":"OG002","value":"159.3","spread":"4.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":"2.87"},{"groupId":"OG001","value":"-17.3","spread":"2.94"},{"groupId":"OG002","value":"-2.8","spread":"2.97"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving A1c <7% at Week 24","description":"Percentage of participants achieving A1C \\< 7%, the American Diabetic Association's defined goal for glycemia, at each dose of saxagliptin plus TZD versus placebo plus TZD at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":null},{"groupId":"OG001","value":"41.8","spread":null},{"groupId":"OG002","value":"25.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24","description":"Mean change from baseline for 0 to 180 minutes PPG AUC achieved at each dose of saxagliptin plus TZD versus placebo plus TZD at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48301","spread":"968.5"},{"groupId":"OG001","value":"47866","spread":"1048.9"},{"groupId":"OG002","value":"47256","spread":"1057.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40255","spread":"919.7"},{"groupId":"OG001","value":"38587","spread":"991.3"},{"groupId":"OG002","value":"44819","spread":"1023.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7849","spread":"740.6"},{"groupId":"OG001","value":"-9269","spread":"794.9"},{"groupId":"OG002","value":"-2690","spread":"820.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":184},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","URINARY TRACT INFECTION","OEDEMA PERIPHERAL","ARTHRALGIA","HEADACHE"]}}}